For Immediate Release: November 3, 2014 Medpace Contact: Mary Kuramoto, +1 513-579-9911 X2523 [email protected] Medpace expands Executive Management Team, adding Kurt A. Brykman as COO, CRO Operations; and Jesse Geiger, COO, Laboratory Operations and CFO. CINCINNATI, OH (November 3, 2014) — Medpace, a global, privately held, full-service contract research organization (CRO) announced it has added Kurt Brykman to its Executive Management team as COO, CRO Operations. In addition, current CFO, Jesse Geiger will take on additional responsibility for Medpace Laboratory Operations in an expanded role. Both positions will report to Dr. August Troendle, current Medpace President and CEO. The organizational change further facilitates Medpace’s continued growth and augments our leadership capacity and succession planning. Kurt Brykman – a proven industry executive in the healthcare industry - was most recently an Officer and Divisional President of a large CRO ranked among the top 5 in terms of revenue. He was a key member of the management team that grew that CRO into the one of the largest clinical research organization in the world. He holds an MBA in Finance and Economics from the J. L. Kellogg Graduate School of Management at Northwestern University and a BS in mathematics from Michigan State University. Jesse Geiger-as the current CFO-has been instrumental in leading Medpace through two equity recapitalizations most recently Cinven in early 2014 - positioning Medpace as a preeminent global CRO. With this heightened management focus on strategic laboratory operations, Medpace further enhances its position as a global provider of central lab services. Prior to his role as Medpace CFO, Mr. Geiger held other management and leadership roles as Corporate Controller, Financial Planning and Analysis Manager, and Director of Capital Markets. He holds a BBA in Accounting from the University of Cincinnati and is a Certified Public Accountant. “The creation of these two positions was critical to support continued Medpace growth,” said August J. Troendle, Medpace President and CEO. “Enhancing management talent provides a catalyst for continued Medpace operational performance - augmenting Medpace capacity at the executive level, and providing a succession plan for the future.” This reorganization and addition of executive industry talent will strengthen Medpace operational teams to better serve sponsors. ### ABOUT MEDPACE Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. Medpace creates strategic therapeutic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval. With 1700+ employees and clinical trial experience in over 45 countries and 6 regions - the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Medpace Imaging Core Lab. For more information, please visit www.medpace.com